Discover why Medis is the company
that leads the way into the future
Hans Brons (CEO)
Hans joined Medis in 2019 as CEO. He brings over 28 years of business and general management experience in technology-focused companies of both corporate, start-up and scale-up sizes. Prior to Medis he led Nemo Healthcare and was (co-)founder of several technology-focused companies. He held several senior and general management positions at Philips Electronics, including Philips Healthcare.
Hans gets intrigued by disruptive technology and leading the transformation from new technology into marketable products and sustainable competitive advantage.
Johan (Hans) HC Reiber (CSO)
Johan (Hans) HC Reiber is co-founder (1989) and former CEO of Medis. He is also founder of the Division of Image Processing (LKEB), initially at the Thoraxcenter in Rotterdam in 1976 and from 1990 at the Leiden University Medical center (LUMC). He is emeritus professor for cardiovascular imaging both at the LUMC and the Interuniversity Cardiology Institute of the Netherlands (ICIN), and member of the Royal Netherlands Academy of Arts and Sciences (KNAW). Hans’ ambition has always been to bring innovative image-based quantitation applications into the hands of the clinician and clinical researcher worldwide. After having served 10 years as CEO of Medis, Hans now serves as Chief Scientific Officer responsible for the Applied Research and he is the primary point-of-contact for internal and external clinical research trials.
Johan Vooren (CCO)
Johan joined Medis early 2020 as Chief Commercial Officer. Prior to joining Medis he has held multiple Senior & Executive positions in various Businesses & Markets in Philips Healthcare and brings with him global sales experience across three continents, Europe, Africa and Asia Pacific.
He has experience in building Business-Market combinations and Product Marketing strategies in both Mature and Emerging Markets; a true commercial leader who brings 25 years of experience in B2B specifically in a commercial environment with a clear focus on and passion for the customer.
Kostas Vlassis (CTO)
Kostas joined Medis in early 2020 as Chief Technology Officer. Previously he held multiple senior technology leadership positions in various sectors like market research, online marketplaces, sustainable technologies and digital healthcare. With over 20 years of experience in a number of key technologies Kostas has led technology teams that delivered world class products and services worldwide. He brings with him the ability to scale-up technology teams to be more efficient and productive while maintaining a cutting edge advantage through rapid product iterations. Kostas has a MSc Information Systems from Brunel University in London and an MBA from Cass Business School, City University of London.
Nicky joined Medis’ supervisory board as a representative of Van Herk Investments in February 2018. Nicky has over 10 years’ experience in a diverse range of international business development- and investment positions in the life sciences and brings experience in the establishment of (public-private) partnerships, the commercialization of medical innovations and technologies, (out)licensing, deal making, spin-off creation and intellectual property management. In addition to her role at Medis, Nicky is the Executive Vice President Global Business Development at SkylineDx, a commercial-stage diagnostics company, Fund Manager for Swanbridge Capital, a Rotterdam-based venture capital firm that funds early stage start-up companies in the life sciences, and supervisory board member at IPaDiC B.V., a start-up company developing an implantable insulin pump.
Carl J.G. Evertsz
Before joining Medis’ supervisory board in 2018, Carl Evertsz consulted Medis in the areas of business and corporate development and corporate finance. Carl has extensive experience founding, leading, and growing innovative medical imaging companies. He actively led international business, corporate and R&D developments, including M&A and technology acquisitions. Amongst others, he was CEO of MeVis Medical Solutions AG, which he led through a successful IPO in 2007, and CEO of MeVis BreastCare, a joint-venture with Siemens founded in 2001. As business angel he served 4 years at SCiLS GmbH as chairman of the advisory board and since 2014 at ScreenPoint Medical B.V. as a non-executive member of the board of directors.
The official start of the Medis Medical Imaging Systems bv company was in 1989 in Leiden, as a spin-off from the Leiden University Medical Center (LUMC), The Netherlands, but actually based already on 15 years of imaging research experience from the Thoraxcenter at the Erasmus University in Rotterdam. The initial work concentrated on creating a commercial version of the QCA (Quantitative Coronary Angiography) application under the name of QCA-CMS (now QAngio XA), the gold standard post-processing software solution for quantitative coronary and left ventricular analysis.
In the early 90’s, the developments expanded towards cardiovascular MR with quantitative solutions for LV function and flow all based on image segmentation techniques, followed by intravascular imaging with IVUS and later OCT, as well as CT for function and coronary plaque burden assessment.
Since the early 2010’s, Medis has also concentrated on innovative solutions for the physiologic assessment of coronary arteries in interventional cardiology, all image-based without a pressure wire and without a drug stimulus. Medis is dedicated to continuously expand the features of all these solutions, where robustness, accuracy and reproducibility are key to its success. These developments are supported by a number of strategic partners.
Medis has been very fortunate that it has established an enormous network of loyal clinical researchers and key opinion leaders around the globe, who provide excellent feedback and scientific publications on early research versions, that are later transferred into clinical solutions with all the necessary regulatory approvals and worldwide services.
For more than 30 years now cardiologists, radiologists, researchers and industry partners worldwide rely on Medis post-processing software, resulting in our installed base of customers in over 40 countries.
Medis headquarters is in Leiden, The Netherlands, but over the years we have established subsidiaries and branch offices in the USA, Japan, United Kingdom, as well as distibutors and local agents in multiple countries.
We believe in empowering medical professionals by continuously innovating the latest cutting-edge technology and integrating these in our analytical solutions.
Our team of professionals take great pride in developing software that gives clinicians and clinical researchers the confidence that they seek. Our goal is to find, develop and support solutions. We come from a history of post-processing cardiovascular imaging. We research to provide technology that captures and quantifies detailed imaging aspects.
« We are committed to improving the diagnosis of cardiovascular imaging and support the subsequent treatment strategies for patients worldwide. »
Providing innovation-driven cardiovascular imaging solutions based on technology and experience. Our high-quality quantification software empowers medical professionals with solutions that support their diagnoses and treatment options.
We aim to adapt to the ever changing cardiovascular imaging environment in order to be flexible enough to find solutions to new challenges. At Medis we strive to constantly provide medical professionals with support worldwide, so that together we can improve patient’s quality of care.